

## NON-EXECUTIVE DIRECTOR RETIREMENT

**Perth, Australia; 24 OCTOBER 2024** - Argenica Therapeutics Limited (ASX: AGN) (“Argenica” or the “Company”), a biotechnology company developing novel therapeutics to reduce brain tissue death after stroke and other neurological conditions, today announces the upcoming retirement of Ms Liddy McCall. The Company confirms that Ms McCall has indicated that she intends to not seek re-election at this year’s AGM on 12 November 2024. Ms McCall has been a member of the Board since 2020 and has made a significant contribution to the Company during her tenure, supporting its listing on the ASX in June 2021 and helping to capitalise and develop a novel neuroprotective drug arising from the University of Western Australia and the Perron Institute for Neurological and Translational Science, known today as ARG-007 and in clinical development for the treatment of stroke.

The Board thanks Ms McCall for her dedication and contribution and wishes her well.

Authorised for release by the Chair and Company Secretary.

For more information please contact: [info@argenica.com.au](mailto:info@argenica.com.au)

### ABOUT ARGENICA

Argenica (ASX: AGN) is developing novel therapeutics to reduce brain tissue death after stroke and other types of brain injury and neurodegenerative diseases to improve patient outcomes. Our lead neuroprotective peptide candidate, ARG-007, has been successfully demonstrated to improve outcomes in pre-clinical stroke models, traumatic brain injury (TBI) and hypoxic ischaemic encephalopathy (HIE). The Company has completed a Phase 1 clinical trial in healthy human volunteers to assess the safety and tolerability of a single dose of ARG-007. Argenica has now initiated a Phase 2 clinical trial in acute ischaemic stroke patients, as well as continuing to generate preclinical data in other neurological conditions.